<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">RSX</journal-id>
<journal-id journal-id-type="hwp">sprsx</journal-id>
<journal-id journal-id-type="nlm-ta">Reprod Sci</journal-id>
<journal-title>Reproductive Sciences</journal-title>
<issn pub-type="ppub">1933-7191</issn>
<issn pub-type="epub">1933-7205</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1933719111432860</article-id>
<article-id pub-id-type="publisher-id">10.1177_1933719111432860</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Mid-Gestation Ovine Cardiomyocytes Are Vulnerable to Mitotic Suppression by Thyroid Hormone</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Chattergoon</surname>
<given-names>Natasha N.</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff1-1933719111432860">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Louey</surname>
<given-names>Samantha</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff1-1933719111432860">1</xref>
<xref ref-type="aff" rid="aff2-1933719111432860">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Stork</surname>
<given-names>Philip</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-1933719111432860">1</xref>
<xref ref-type="aff" rid="aff3-1933719111432860">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Giraud</surname>
<given-names>George D.</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff1-1933719111432860">1</xref>
<xref ref-type="aff" rid="aff2-1933719111432860">2</xref>
<xref ref-type="aff" rid="aff4-1933719111432860">4</xref>
<xref ref-type="aff" rid="aff5-1933719111432860">5</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Thornburg</surname>
<given-names>Kent L.</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff1-1933719111432860">1</xref>
<xref ref-type="aff" rid="aff2-1933719111432860">2</xref>
<xref ref-type="aff" rid="aff4-1933719111432860">4</xref>
<xref ref-type="corresp" rid="corresp1-1933719111432860"/>
</contrib>
</contrib-group>
<aff id="aff1-1933719111432860">
<label>1</label>Heart Research Center, Oregon Health &amp; Science University, Portland, OR, USA</aff>
<aff id="aff2-1933719111432860">
<label>2</label>Department of Medicine (Cardiovascular Medicine), Oregon Health &amp; Science University, Portland, OR, USA</aff>
<aff id="aff3-1933719111432860">
<label>3</label>Vollum Institute for Advanced Biomedical Research, Oregon Health &amp; Science University, Portland, OR, USA</aff>
<aff id="aff4-1933719111432860">
<label>4</label>Department of Physiology and Pharmacology, Oregon Health &amp; Science University, Portland, OR, USA</aff>
<aff id="aff5-1933719111432860">
<label>5</label>Cardiology, Portland Veterans Affairs Medical Center, Portland, OR, USA</aff>
<author-notes>
<corresp id="corresp1-1933719111432860">Kent L. Thornburg, Oregon Health &amp; Science University, 3303 SW Bond Ave, CH15H, Portland, OR 97239, USA Email: <email>thornbur@ohsu.edu</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>6</month>
<year>2012</year>
</pub-date>
<volume>19</volume>
<issue>6</issue>
<fpage>642</fpage>
<lpage>649</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="society">Society for Gynecologic Investigation</copyright-holder>
</permissions>
<abstract>
<p>Circulating fetal 3,3′,5-tri-iodo-<sc>l</sc>-thyronine (T<sub>3</sub> ) is maintained at very low levels until a dramatic prepartum surge. 3,3′,5-Tri-iodo-<sc>l</sc>-thyronine inhibits serum-stimulated proliferation in near-term ovine cardiomyocytes, but it is not known whether midgestation myocytes are also inhibited. Because early cessation of cardiomyocyte mitosis would result in an underendowed heart, we hypothesized that 0.67 gestation (100 of 145 days gestation) ovine cardiomyocytes would be insensitive to suppressive growth effects of T<sub>3</sub> . These younger cardiomyocytes were grown with T<sub>3</sub> in 10% serum-enriched media for 24 hours. Physiological (0.37, 0.75, and 1.5 nmol/L) concentrations of T<sub>3</sub> dramatically suppressed mitotic activity in cardiomyocytes (<italic>P </italic>&lt; .001). 3,3′,5-Tri-iodo-<sc>l</sc>-thyronine stimulated phosphorylation of extracellular signal-regulated kinase and AKT (also known as Protein Kinase B [PKB]) signaling pathways. Nevertheless, the protein content of the cell cycle suppressor, p21, increased 2-fold (<italic>P</italic> &lt; .05), and promoter, cyclin D1, decreased by 50%. Contrary to our hypothesis, elevated levels of T<sub>3</sub> powerfully inhibit proliferation of midgestation fetal cardiomyocytes. Thus, midgestation maternal hyperthyroidism might lead to an underendowed fetal myocardium.</p>
</abstract>
<kwd-group>
<kwd>fetal heart</kwd>
<kwd>cardiomyocyte proliferation</kwd>
<kwd>thyroid hormone</kwd>
<kwd>p21</kwd>
<kwd>cyclin D1</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-1933719111432860">
<title>Introduction</title>
<p>At birth, nearly 60% to 70% of ovine cardiomyocytes have gained a second nucleus and no longer divide.<sup>
<xref ref-type="bibr" rid="bibr1-1933719111432860">1</xref>
</sup> Their loss of mitotic potential occurs through a process known as terminal differentiation,<sup>
<xref ref-type="bibr" rid="bibr2-1933719111432860">2</xref>,<xref ref-type="bibr" rid="bibr3-1933719111432860">3</xref>
</sup> which begins at 110 days of gestation and continues until parturition at about 145 days. Before 110 days, mononucleated fetal cardiomyocytes divide rapidly to build the cellular endowment of the growing myocardium.<sup>
<xref ref-type="bibr" rid="bibr1-1933719111432860">1</xref>
</sup> The process of terminal cardiomyocyte maturation in sheep is predominantly prenatal and is thought to more closely represent human heart development.<sup>
<xref ref-type="bibr" rid="bibr4-1933719111432860">4</xref>
</sup> This precocious growth pattern differs from the pattern in the altricial rat and mouse heart, in which the terminal differentiation process does not begin until after birth; only about 7% of cardiomyocytes are binucleated at birth but more than 95% of cardiomyocytes are binucleated by 2 weeks of postnatal age.<sup>
<xref ref-type="bibr" rid="bibr5-1933719111432860">5</xref>
</sup>
</p>
<p>An adequate endowment of mature cardiomyocytes is important for the postnatal transition when left ventricular cardiomyocytes contract against a sudden doubling of arterial pressure.<sup>
<xref ref-type="bibr" rid="bibr6-1933719111432860">6</xref>
</sup> Beyond birth, the heart enlarges through the hypertrophic enlargement of individual cardiomyocytes and the expansion of the extracellular matrix with only a small contribution by proliferation.<sup>
<xref ref-type="bibr" rid="bibr7-1933719111432860">7</xref>,<xref ref-type="bibr" rid="bibr8-1933719111432860">8</xref>
</sup> The number of cardiomyocytes contained within the heart at birth can vary according to prenatal hormonal conditions.<sup>
<xref ref-type="bibr" rid="bibr4-1933719111432860">4</xref>,<xref ref-type="bibr" rid="bibr9-1933719111432860">9</xref>
</sup> Fetal growth factors like insulin-like growth factor 1,<sup>
<xref ref-type="bibr" rid="bibr10-1933719111432860">10</xref>
</sup> angiotensin II (Ang II),<sup>
<xref ref-type="bibr" rid="bibr11-1933719111432860">11</xref>
</sup> and cortisol<sup>
<xref ref-type="bibr" rid="bibr12-1933719111432860">12</xref>
</sup> independently stimulate proliferation rates of near-term ovine cardiomyocytes, whereas the rates are suppressed by atrial natriuretic peptide<sup>
<xref ref-type="bibr" rid="bibr13-1933719111432860">13</xref>
</sup> and thyroid hormone.<sup>
<xref ref-type="bibr" rid="bibr14-1933719111432860">14</xref>
</sup> In the living sheep fetus, proliferation rates are also suppressed under conditions of placental insufficiency.<sup>
<xref ref-type="bibr" rid="bibr15-1933719111432860">15</xref>
</sup>
</p>
<p>The ovine thyroid gland begins to secrete thyroxine (T<sub>4</sub>) around 50 days gestational age (dGA)<sup>
<xref ref-type="bibr" rid="bibr16-1933719111432860">16</xref>,<xref ref-type="bibr" rid="bibr17-1933719111432860">17</xref>
</sup> and the concentration of T<sub>4</sub> in plasma slowly rises over the first 2/3 of gestation. However, T<sub>4</sub> itself has a minor influence on cardiomyocyte growth and function because of its low potency. The affinity of T<sub>4</sub> for alpha and β-thyroid hormone receptors (TRα and TRβ) is nearly 10 to 15 times less than for 3,3′,5-tri-iodo-<sc>l</sc>-thyronine (T<sub>3</sub>).<sup>
<xref ref-type="bibr" rid="bibr18-1933719111432860">18</xref>
</sup> 3,3′,5-Tri-iodo-<sc>l</sc>-thyronine is highly effective in binding thyroid receptors (TRα1 and TRβ1). Over the last few weeks of gestation, fetal T<sub>3</sub> levels increase by nearly10-fold as T<sub>4</sub> is converted to T<sub>3</sub> under the influence of ever increasing deiodinase activity in peripheral tissues.<sup>
<xref ref-type="bibr" rid="bibr19-1933719111432860">19</xref>
<xref ref-type="bibr" rid="bibr20-1933719111432860"/>–<xref ref-type="bibr" rid="bibr21-1933719111432860">21</xref>
</sup> Deiodinase gene expression increases under the influence of cortisol, which is elevated dramatically in the last few weeks of gestation consequent to the maturation of steroid synthetic activity in the adrenal gland.<sup>
<xref ref-type="bibr" rid="bibr21-1933719111432860">21</xref>,<xref ref-type="bibr" rid="bibr22-1933719111432860">22</xref>
</sup>
</p>
<p>We previously reported that physiological concentrations of T<sub>3</sub> are powerful suppressants of serum-stimulated proliferation in cardiomyocytes isolated from late-gestation fetal sheep hearts (∼0.9 gestation)<sup>
<xref ref-type="bibr" rid="bibr14-1933719111432860">14</xref>
</sup> and that the elevations of T<sub>3</sub> in the near-term fetus stimulate maturation of cardiomyocytes.<sup>
<xref ref-type="bibr" rid="bibr23-1933719111432860">23</xref>
</sup> At this stage of development, plasma levels of T<sub>3</sub> are rising; consequently by the time of parturition, nearly 70% of cardiomyocytes will have exited the cell cycle.<sup>
<xref ref-type="bibr" rid="bibr1-1933719111432860">1</xref>
</sup> However, it is not clear whether younger more rapidly dividing cardiomyocytes are as sensitive to elevations in T<sub>3</sub> as older ones.</p>
<p>It was once believed that maternal thyroid hormones did not cross the placenta. However, recent evidence proves the contrary.<sup>
<xref ref-type="bibr" rid="bibr24-1933719111432860">24</xref>
<xref ref-type="bibr" rid="bibr25-1933719111432860"/>–<xref ref-type="bibr" rid="bibr26-1933719111432860">26</xref>
</sup> It is now well-accepted that maternal thyroid levels influence fetal levels even before the fetal thyroid is active.<sup>
<xref ref-type="bibr" rid="bibr24-1933719111432860">24</xref>,<xref ref-type="bibr" rid="bibr27-1933719111432860">27</xref>
</sup> There are a number of putative transporters for thyroid hormone in the placenta but monocarboxylate transporter 8 (MCT8) is thought to be the most important.<sup>
<xref ref-type="bibr" rid="bibr28-1933719111432860">28</xref>
</sup> Thus, if T<sub>3</sub> levels became abnormally elevated in fetuses and if cardiomyocytes were sensitive to T<sub>3</sub>, the resulting suppression of cardiomyocyte proliferation would lead to a heart with an inadequate endowment of cardiomyocytes at birth; such a heart might suffer compromised function later in life.</p>
<p>We hypothesized that cardiomyocytes from 100 dGA (0.6 gestation) fetal hearts would be less sensitive to mitotic suppression with T<sub>3</sub> exposure than 135 dGA fetal cardiomyocytes previously studied. Resistance to a T<sub>3</sub> suppressive effect would be a protective mechanism to prevent harm that could be caused by inadequate proliferation at a stage when building the myocardium is crucial. In keeping with the hypothesis, we also reasoned that unlike older myocytes, the expression levels of the cell cycle inhibitory protein, p21, would not be elevated by T<sub>3</sub> nor would the protein levels of the cell cycle promoter, cyclin D1, be suppressed. We supposed that signaling cascades associated with proliferation, including the extracellular signal-regulated kinase (ERK) branch of the mitogen-activated protein kinase (MAPK) cascade and the phosphoinositol-3 kinase [PI3K]/AKT pathways, would, likewise, not be altered by T<sub>3</sub>. To test the hypothesis, we isolated cardiac myocytes from sheep fetuses that were ∼100 days gestation and determined the degree to which T<sub>3</sub> affected mitosis and associated cell signaling.</p>
</sec>
<sec id="section2-1933719111432860" sec-type="materials|methods">
<title>Materials and Methods</title>
<sec id="section3-1933719111432860">
<title>Animals</title>
<p>Animals were studied and cared for in accordance with the Institutional Animal Care and Use Committee at the Oregon Health and Science University (Portland, Oregon). Primary cultures of cardiomyocytes were obtained from noninstrumented, control fetal sheep (<italic>Ovis aries</italic>; mixed western breed) at 102 ± 3 dGA, where term is ∼145 dGA. The fetal cardiac myocytes that comprise the myocardium at ∼100 dGA are phenotypically homogeneous and are mononucleated.<sup>
<xref ref-type="bibr" rid="bibr1-1933719111432860">1</xref>
</sup>
</p>
</sec>
<sec id="section4-1933719111432860">
<title>Materials</title>
<p>3,3′,5-Tri-iodo-<sc>l</sc>-thyronine (thyroid hormone), 5-bromo-2′-deoxyuridine (BrdU), insulin–transferrin–sodium selenite (ITSS), penicillin–streptomycin–amphotericin B (PSA), Type XIV protease, and laminin were obtained from Sigma-Aldrich (St Louis, Missouri). Type II collagenase was obtained from Worthington Biochemicals (Lakewood, New Jersey).</p>
</sec>
<sec id="section5-1933719111432860">
<title>Antibodies for Western Blot Analyses</title>
<p>The following antibodies were obtained from Cell Signaling (Danvers, Massachusetts). Phospho-p44/42 MAPK (ERK1/2) rabbit polyclonal antibody detects endogenous levels of p44 and p42 MAPK (ERK1 and ERK2) when phosphorylated either individually or dually at Thr202 and Tyr204. Phospho-AKT (Ser473; D9E) XP rabbit monoclonal antibody detects endogenous levels of AKT only when phosphorylated at Ser473. AKT rabbit polyclonal antibody detects endogenous levels of total AKT1, AKT2, and AKT3 proteins. Rabbit monoclonal α-tubulin detects endogenous levels of total α-tubulin protein and does not cross-react with recombinant β-tubulin. Mouse monoclonal p21 Waf1/Cip1 (DCS60) antibody detects endogenous levels of total p21 protein. The antibody does not cross-react with other cyclin-dependent kinase inhibitors and recognizes the amino-terminal portion of p21. The remaining antibodies were obtained from Santa Cruz Biotech, Inc. (Santa Cruz, California). Mouse monoclonal cyclin D1 recognizes full-length peptide and does not cross-react with cyclin D3. Mouse monoclonal ERK2 antibody recognizes C-terminus of MAPK p42. Mouse monoclonal TRα1/β1 recognizes the ligand binding domain of each receptor (TRα1: 47 kDa; TRβ1: 58 kDa). Horseradish peroxidase linked secondary antibodies (goat anti-rabbit IgG and horse anti-mouse IgG) were obtained from Cell Signaling.</p>
</sec>
<sec id="section6-1933719111432860">
<title>Cardiac Myocyte Isolation</title>
<p>Ewes were euthanized by intravenous injection of a commercial solution of sodium pentobarbital (SomnaSol, ∼80 mg/kg, Butler Schein Animal Health, Dublin, Ohio). Fetuses received a bolus dose of heparin (5000 U, Baxter, Deerfield, Illinois), followed by 5 mL of saturated potassium chloride (KCl) into the umbilical vein to arrest the heart in diastole. Fetuses were weighed and the heart excised, trimmed in a standard way, blotted dry, and weighed. Hearts were enzymatically dissociated as previously described by our laboratory.<sup>
<xref ref-type="bibr" rid="bibr29-1933719111432860">29</xref>
</sup> Briefly, hearts were perfused in a retrograde manner with gassed solutions (95% O<sub>2</sub> and 5% CO<sub>2</sub>, 39°C); tyrodes buffer for 5 minutes ([no calcium added]; 140 mmol/L NaCl, 5 mmol/L KCl, 1 mmol/L MgCl<sub>2</sub>.6H<sub>2</sub>O, 10 mmol/L glucose, and 10 mmol/L 4-(2-hydroxyethyl)-1-piperazineethane sulfonic acid (HEPES); pH adjusted to 7.35 with NaOH) until the vessels were clear of blood; 2 minutes with 160 U/mL type II and 0.78 U/mL type XIV protease in tyrodes buffer to digest the tissue; finally, 5 minutes with a high potassium, calcium-free Kraftbrühe (KB) solution (74 mmol/L glutamic acid, 30 mmol/L KCl, 30 mmol/L KH<sub>2</sub>PO<sub>4</sub>, 20 mmol/L taurine, 3 mmol/L MgSO<sub>4</sub>, 0.5 mmol/L ethylene glycol tetraacetic acid (EGTA), 10 mmol/L HEPES, and 10 mmol/L glucose; pH adjusted to 7.37 using KOH). The left ventriclular (LV) and right ventricular (RV) free walls were dissected from the heart and placed into separate tubes containing 20 mL KB solution. The tissue was gently agitated to release cardiomyocytes.</p>
</sec>
<sec id="section7-1933719111432860">
<title>Cardiomyocyte Cultures</title>
<p>Cardiomyocytes were cultured as previously described by our laboratory.<sup>
<xref ref-type="bibr" rid="bibr13-1933719111432860">13</xref>,<xref ref-type="bibr" rid="bibr14-1933719111432860">14</xref>
</sup> The freshly isolated slurry of myocytes rested for 30 to 60 minutes at room temperature (RT) before centrifugation and resuspension in sterile serum media (10% fetal bovine serum; Invitrogen, Carlsbad, California); Dulbecco's Minimum Eagle Medium (DMEM) low glucose: 5.56 mmol/L <sc>d</sc>-glucose, 4 mmol/L <sc>l</sc>-glutamine, 1 mmol/L sodium pyruvate, 5.33 mmol/L KCl, 0.4 mmol/L glycine, pH 7.4 (Invitrogen, #11885-084) supplemented with 10 mg/L of ITSS, and 10 mL/L PSA. All cultures were performed at 39°C and 5% CO<sub>2</sub>. Cells were preplated twice to remove non-myocyte cells (2 hours each time). Myocytes were then seeded on 22 × 22 mm<sup>2</sup> glass coverslips (for measurement of proliferation) or in 6-well plates (for protein analysis). Coverslips and 6-well plates were coated with laminin (4 mg/mL) for at least 4 hours and aspirated just before plating at a density of 1.5 × 10<sup>5</sup> cells per coverslip and 5 × 10<sup>5</sup> cells per well. Cardiomyocytes were incubated in serum media for 24 hours. Cells were then incubated in serum free (SF) media for 48 hours, and the media was changed again to fresh SF media for 24 hours before treatment; treatment commenced on culture day 5 for all experiments.</p>
</sec>
<sec id="section8-1933719111432860">
<title>Proliferation Studies (BrdU Uptake)</title>
<p>In order to determine the effects of T<sub>3</sub> on cardiomyocyte proliferation, we measured BrdU incorporation (10 μmol/L) as an index of cell proliferation in 2 groups of cultured fetal cardiomyocytes: (1) 48 hour in SF medium with increasing T<sub>3</sub> doses and (2) 48 hour of serum medium with increasing T<sub>3</sub> concentrations. We chose to treat with media containing T<sub>3</sub> with and without serum because we wanted to compare both conditions with our previous studies in near-term fetal sheep. Concentrations of T<sub>3</sub> ranged from those occurring normally in fetal sheep during gestation (0.37, 0.75, and 1.5 nmol/L)<sup>
<xref ref-type="bibr" rid="bibr19-1933719111432860">19</xref>
</sup> to those that might occur under pathological conditions (3, 10, and 100 nmol/L).<sup>
<xref ref-type="bibr" rid="bibr14-1933719111432860">14</xref>,<xref ref-type="bibr" rid="bibr30-1933719111432860">30</xref>,<xref ref-type="bibr" rid="bibr31-1933719111432860">31</xref>
</sup> The total T<sub>3</sub> levels in the last one third of gestation was represented as 0.37 nmol/L, approximating the normal circulating levels near 100 dGA, and 1.5 nmol/L, the concentration found just prior to birth.<sup><xref ref-type="bibr" rid="bibr32-1933719111432860">32</xref>,<xref ref-type="bibr" rid="bibr33-1933719111432860">33</xref></sup> Many in vitro studies describing T<sub>3</sub> actions use only the higher concentrations of T<sub>3</sub>.<sup><xref ref-type="bibr" rid="bibr30-1933719111432860">30</xref>,<xref ref-type="bibr" rid="bibr31-1933719111432860">31</xref>,<xref ref-type="bibr" rid="bibr34-1933719111432860">34</xref></sup> In our study, we used the higher conventional concentrations exclusively to determine T<sub>3</sub>'s effect on cell cycle proteins to provide comparisons with previously published studies. At the end of the study, cardiomyocytes were fixed in ice-cold ethanol for staining procedures.</p>
</sec>
<sec id="section9-1933719111432860">
<title>5-Bromo-2′-deoxyuridine Uptake Analysis</title>
<p>Cells were permeabilized by incubating with 5 μg/mL DNase as described previously<sup>
<xref ref-type="bibr" rid="bibr11-1933719111432860">11</xref>
</sup> for 30 minutes at 37°C. Fixed cultured cardiomyocytes were then incubated with mouse anti-myosin heavy chain α/β (1:5000, ab15, Abcam, Cambridge, Massachusetts) and rat anti-BrdU (1:500, ab6326, Abcam) antibodies overnight at 4°C. Following phosphate-buffered saline (PBS) washes, cells were incubated in anti-mouse rhodamine red (1:200, Jackson ImmunoResearch, West Grove, Pennsylvania) and anti-rat fluorescein isothiocyanate (FITC; 1:200, Jackson ImmunoResearch, West Grove, Pennsylvania) secondary antibodies for 2 hours at RT. Coverslips were mounted onto slides using Vectashield Hardset mounting medium with 4′,6-diamidino-2-phenylindole (DAPI) (Vector Laboratories, Burlingame, California) and stored in the dark overnight at 4°C to allow the mounting medium to set.<sup>
<xref ref-type="bibr" rid="bibr14-1933719111432860">14</xref>
</sup> The portion of BrdU-positive myocytes was determined in a random sample of 300 (minimum) myocytes using fluorescence microscopy (×400 magnification; Zeiss Axiophot, Bartels &amp; Stout, Bellevue, Washington) with FITC (excitation: 450-490 nm and emission: 515-565 nm) and TRITC filters (tetramethylrhodamine isothiocyanate, excitation: 485 nm and emission: 515-530 nm). 5-Bromo-2′-deoxyuridine-positive cardiomyocytes were identified as those that stained positive for both myosin (rhodamine) and punctuate nuclei (FITC), indicating BrdU incorporation.</p>
</sec>
<sec id="section10-1933719111432860">
<title>Thyroid Hormone Signaling</title>
<p>Fetal cardiomyocytes were prepared in 6-well plates as described above for signaling studies on day 5 of culture. In order to isolate the signaling cascades triggered by T<sub>3</sub> alone, we performed these studies in SF media to remove the influence of serum.<sup>
<xref ref-type="bibr" rid="bibr30-1933719111432860">30</xref>,<xref ref-type="bibr" rid="bibr31-1933719111432860">31</xref>,<xref ref-type="bibr" rid="bibr35-1933719111432860">35</xref>
</sup> The first group of cells was incubated with increasing concentrations of T<sub>3</sub> in SF media (1.5, 10, and 100 nmol/L) for 24 hours at 39°C. These were used to determine whether T<sub>3</sub> affected p21 (cell cycle inhibitor) and cyclin D1 (cell cycle promoter) expression. These same lysates were used to determine whether the thyroid hormone receptor isoforms (TRα1 and TRβ1) are altered by media conditions or concentration of T<sub>3</sub> used. We also determined the rapid activation profile of ERK and AKT by phosphorylation (pERK and pAKT) at the same concentrations following a 10-minute stimulation. Cell lysates were prepared for protein analysis as described below.</p>
</sec>
<sec id="section11-1933719111432860">
<title>Western Blot Analysis</title>
<p>After the appropriate incubation period, medium was aspirated, cardiomyocytes were rinsed in ice-cold 1× PBS, lysed (5 mmol/L Tris-HCl, 5 mmol/L EGTA, 5 mmol/L EDTA, 0.06% sodium dodecyl sulfate (SDS), protease inhibitor mini-complete tablet [Roche, Indiana], and phosphatase inhibitor cocktail I and II [Sigma-Aldrich]), and collected into prechilled tubes. Protein concentration was quantified by BCA assay (Pierce, Rockford, Illinois). Equal amounts of total protein/sample (10 μg) were separated by SDS polyacrylamide gel electrophoresis (PAGE) on a 10% Tris-glycine gel and transferred to a nitrocellulose membrane (Optitran BA-S 83, Whatman, New Jersey). Membranes were blocked with 5% milk in 1× Tris-buffered saline + 0.01% Tween 20 (TBS-T) buffer for 1 hour at RT. Membranes were incubated with primary antibodies (1:1000) overnight at 4°C in 4% bovine serum albumin (Sigma-Aldrich) in 1× TBS-T buffer. Membranes were washed in large volumes of TBS-T before exposure to the secondary antibody (1:5000) in 5% milk–TBS-T for 1 hour at RT. Antibody binding was detected using chemiluminescence (SuperSignal, Pierce, Illinois); protein expression was quantified from a digitized image of the blot using NIH Image J (Version 1.4; NIH). Protein density was normalized to total protein and expressed as phospho-protein/total protein (ERK and AKT) or protein/α-tubulin (TRα1/β1, p21, and cyclin D1).</p>
</sec>
<sec id="section12-1933719111432860">
<title>Statistical Analysis</title>
<p>Only data from left ventricular cells are reported because responses in the RV were similar to those from the LV. On average, BrdU incorporation was slightly lower in RV, but the trends between ventricles were otherwise similar. A minimum of 300 cells per treatment group were assessed for BrdU incorporation and reported as a percentage of total number of cardiomyocytes counted. One-way analysis of variance (ANOVA) was used to analyze BrdU uptake as well as Western blot density. If justified by ANOVA, differences were further analyzed by Tukey multiple comparison post hoc test for the differences between treatment groups. Statistical significance was set at <italic>P</italic> &lt; .05. Data are presented as mean ± SEM.</p>
</sec>
</sec>
<sec id="section13-1933719111432860">
<title>Results</title>
<sec id="section14-1933719111432860">
<title>5-Bromo-2′-deoxyuridine Uptake</title>
<p>
<xref ref-type="fig" rid="fig1-1933719111432860">Figure 1</xref> shows a single 100 day cardiomyocyte positively labeled with BrdU and several other unlabeled cardiomyocytes with myofibrils stained for myosin heavy chain α and β (Figure <xref ref-type="fig" rid="fig1-1933719111432860">1</xref>). 3,3′,5-Tri-iodo-<sc>l</sc>-thyronine did not affect BrdU incorporation rates under SF culture conditions, which were on the order of 12% (<xref ref-type="fig" rid="fig2-1933719111432860">Figure 2A</xref>), and much higher than seen later in gestation.<sup>
<xref ref-type="bibr" rid="bibr14-1933719111432860">14</xref>,<xref ref-type="bibr" rid="bibr36-1933719111432860">36</xref>
</sup> Proliferation rates rose dramatically to ∼25% when serum was added to the medium (<xref ref-type="fig" rid="fig2-1933719111432860">Figure 2B</xref>). However, contrary to our original hypothesis, T<sub>3</sub> (at all concentrations tested) reduced BrdU incorporation rates in the stimulatory environment of serum-rich media (<italic>P</italic> &lt; .001, <xref ref-type="fig" rid="fig2-1933719111432860">Figure 2B</xref>). Also of note, there was a dose-dependent decrease in BrdU uptake at lower T<sub>3</sub> concentrations; proliferation was decreased between serum (0.0 nmol/L T<sub>3</sub>) and 0.37 nmol/L T<sub>3</sub> (<italic>P</italic> &lt; .01), which was further decreased by 0.75 nmol/L T<sub>3</sub> (<italic>P</italic> &lt; .05). There was no further statistical reduction in BrdU uptake when compared with 1.5 nmol/L T<sub>3</sub>; this latter concentration appeared to represent a plateau in the suppression of proliferation with no further inhibition at higher doses.</p>
<fig id="fig1-1933719111432860" position="float">
<label>Figure 1.</label>
<caption>
<p>5-Bromo-2′-deoxyuridine (BrdU) uptake in proliferating fetal sheep cardiomyocytes in vitro. After 48-hour incubation with BrdU, positive myocytes are marked by fluorescein isothiocyanate (green) staining in the nuclei of cells that also stained for myosin (red). Image shown is at ×400 magnification.</p>
</caption>
<graphic alternate-form-of="fig1-1933719111432860" xlink:href="10.1177_1933719111432860-fig1.tif"/>
</fig>
<fig id="fig2-1933719111432860" position="float">
<label>Figure 2.</label>
<caption>
<p>5-Bromo-2′-deoxyuridine (BrdU; 10 μmol/L) incorporation in left ventricular cardiomyocytes from 100 dGA fetal sheep. A, T<sub>3</sub> has no effect on BrdU incorporation of cells treated in serum free media but (B) inhibits BrdU uptake stimulated by 10% fetal bovine serum at all concentrations of T<sub>3</sub> used. Data are mean ± standard error of mean, each bar n = 7, ##<italic>P</italic> &lt; .01, ###<italic>P</italic> &lt; .001 versus serum control, *<italic>P</italic> &lt; .05 versus T<sub>3</sub> 0.37 nmol/L.</p>
</caption>
<graphic alternate-form-of="fig2-1933719111432860" xlink:href="10.1177_1933719111432860-fig2.tif"/>
</fig>
</sec>
<sec id="section15-1933719111432860">
<title>Roles of p21 and Cyclin D1</title>
<p>Protein levels of TRα1 or TRβ1 were determined by Western blot analysis of lysates of cells incubated for 24 hours in SF media or T<sub>3</sub> (1.5, 10, and 100 nmol/L) in SF media (Figure <xref ref-type="fig" rid="fig3-1933719111432860">3</xref>). Protein levels were also measured in cells grown in serum-rich media. Interestingly, there was no difference in TRα1 or TRβ1 levels between SF and serum-rich conditions (<xref ref-type="fig" rid="fig3-1933719111432860">Figure 3</xref>). There was no effect of T<sub>3</sub> concentration on receptor expression of either major isoform of the thyroid receptor. The cell cycle inhibitor p21 was upregulated in SF conditions after 24 hours of T<sub>3</sub> exposure at increasing doses (<xref ref-type="fig" rid="fig4-1933719111432860">Figure 4</xref>, <italic>P</italic> &lt; .05). 3,3′,5-Tri-iodo-<sc>l</sc>-thyronine (1.5 nmol/L) stimulated p21 protein expression in a dose response fashion. Cyclin D1 levels were significantly decreased by T<sub>3</sub> in cardiomyocytes compared with cells in SF control (<xref ref-type="fig" rid="fig5-1933719111432860">Figure 5</xref>). The expression of p21 and cyclin D1 was not different between SF and serum-rich conditions alone.</p>
<fig id="fig3-1933719111432860" position="float">
<label>Figure 3.</label>
<caption>
<p>Effect of culture conditions on thyroid receptor expression. Both TRα1 and TRβ1 protein levels are not different between serum and serum free conditions. Addition of T<sub>3</sub> did not alter the receptor expression. Data are mean ± standard error of mean, each bar n = 7.</p>
</caption>
<graphic alternate-form-of="fig3-1933719111432860" xlink:href="10.1177_1933719111432860-fig3.tif"/>
</fig>
<fig id="fig4-1933719111432860" position="float">
<label>Figure 4.</label>
<caption>
<p>Dose-dependent protein expression of p21 to T<sub>3</sub>. Exposure to T<sub>3</sub> for 24 hours resulted in dose-dependently increased protein levels of the cell cycle inhibitor p21. Data are mean ± standard error of mean, each bar n = 7, *<italic>P</italic> &lt; .05, and **<italic>P</italic> &lt; .01 versus serum free control.</p>
</caption>
<graphic alternate-form-of="fig4-1933719111432860" xlink:href="10.1177_1933719111432860-fig4.tif"/>
</fig>
<fig id="fig5-1933719111432860" position="float">
<label>Figure 5.</label>
<caption>
<p>Dose-dependent protein expression of cyclin D1 to T<sub>3</sub>. Exposure to T<sub>3</sub> for 24 hours resulted in dose dependently decreased protein levels of the cell cycle promoter cyclin D1. Data are mean ± standard error of mean, each bar n = 7, *<italic>P</italic> &lt; .05, and **<italic>P</italic> &lt; .01 versus serum free control.</p>
</caption>
<graphic alternate-form-of="fig5-1933719111432860" xlink:href="10.1177_1933719111432860-fig5.tif"/>
</fig>
</sec>
<sec id="section16-1933719111432860">
<title>3,3′,5-Tri-iodo-<sc>l</sc>-thyronine Signaling: Role of ERK and AKT</title>
<p>Phosphorylated ERK (pERK) and Akt (pAKT) were determined by Western blot analysis of lysates of cardiomyocytes that were exposed to a 10-minute bout of T<sub>3</sub> at 3 different concentrations: 1.5, 10, and 100 nmol/L (Figure <xref ref-type="fig" rid="fig6-1933719111432860">6</xref>). pERK expression increased with increasing T<sub>3</sub> concentration (<xref ref-type="fig" rid="fig6-1933719111432860">Figure 6A</xref>; <italic>P</italic> &lt; .05), while pAKT was elevated equally without an upward trend with increasing T<sub>3</sub> doses (<xref ref-type="fig" rid="fig6-1933719111432860">Figure 6B</xref>, <italic>P</italic> &lt; .05). Serum-free levels of both pERK and pAKT were significantly lower than levels in the presence of serum (<italic>P</italic> &lt; .05).</p>
<fig id="fig6-1933719111432860" position="float">
<label>Figure 6.</label>
<caption>
<p>Activation of ERK and AKT (also known as Protein Kinase B [PKB]) by T<sub>3</sub>. Following an acute exposure to T<sub>3</sub>, ERK phosphorylation is greater with increasing T<sub>3</sub> concentrations (A). AKT phosphorylation, however, increases equally with all three doses of T<sub>3</sub>. Data are mean ± standard error of mean, each bar n = 7, *<italic>P</italic> &lt; .05, and **<italic>P</italic> &lt; .01 versus serum free control. ERK indicates extracellular signal-related kinase; T<sub>3</sub>, 3,3′,5-tri-iodo-l-thyronine.</p>
</caption>
<graphic alternate-form-of="fig6-1933719111432860" xlink:href="10.1177_1933719111432860-fig6.tif"/>
</fig>
</sec>
</sec>
<sec id="section17-1933719111432860">
<title>Discussion</title>
<p>Our findings demonstrate that 100 dGA ovine cardiomyocytes are not protected from the growth suppressive actions of thyroid hormone. This was shown in 2 ways: (1) BrdU uptake was decreased with increasing T<sub>3</sub> levels in a dose-response manner, and (2) BrdU uptake was maximally reduced by 70% in the presence of 1.5 nmol/L T<sub>3</sub> in the more immature 100 days myocyte and about the same degree of suppression of 74% at 1.5 nmol/L T<sub>3</sub> in the older fetal cardiomyocytes. This finding did not support our hypothesis. We had reasoned that the myocardium in the younger fetus would have been more protected from mitosis suppression by T<sub>3</sub>. Such resistance would prevent cardiomyocyte replication at a stage when cardiomyocytes are not ordinarily exposed to significant levels of T<sub>3</sub> and when myocyte numbers are rapidly increasing.</p>
<p>Baseline BrdU uptake rates, without serum enrichment, were 10% to 12% in 100 dGA cardiomyocytes compared with 1% to 2% in 135 dGA cardiomyocyte experiments previously published.<sup>
<xref ref-type="bibr" rid="bibr14-1933719111432860">14</xref>
</sup> The younger cardiomyocytes showed serum-stimulated BrdU uptake rates of ∼25% when compared with ∼10% in the 135 dGA cells.<sup>
<xref ref-type="bibr" rid="bibr14-1933719111432860">14</xref>
</sup> The age difference in proliferative activity was expected because myocytes from the 100 dGA time point are nearly all mononucleated and are normally proliferating at a higher rate in vivo. As term approaches, myocyte cell cycle activity is known to decrease, an increasing number of myocytes are terminally differentiated (binucleated) and have exited the cell cycle.<sup>
<xref ref-type="bibr" rid="bibr1-1933719111432860">1</xref>
</sup>
</p>
<p>3,3′,5-Tri-iodo-<sc>l</sc>-thyronine did not suppress the rates of BrdU uptake among cardiomyocytes under SF conditions, even at the highest doses tested. A similar effect was previously found in near-term ovine cardiomyocytes.<sup>
<xref ref-type="bibr" rid="bibr14-1933719111432860">14</xref>
</sup> Thus, a sustained level of mitosis, as measured by BrdU uptake, continued in the presence of T<sub>3</sub> even though the cell cycle suppressant protein, p21, was upregulated and the cell cycle promoter, cyclin D1, was depressed in the presence of T<sub>3</sub> at all concentrations. These are not apparently due to an altered expression pattern of the 2 most common receptors, TRα1 and TRβ1. The retention of a basal level of proliferation, while interesting, is not likely to be physiologically important because SF conditions are not encountered in the living fetal heart. We speculate that under SF conditions T<sub>3</sub> stimulates a known insulin-sensitive cardiomyocyte survival pathway in which the PI3K/AKT phosphorylation pathway is activated.<sup>
<xref ref-type="bibr" rid="bibr37-1933719111432860">37</xref>,<xref ref-type="bibr" rid="bibr38-1933719111432860">38</xref>
</sup>
</p>
<p>We found that T<sub>3</sub> activates both ERK and AKT in fetal cardiomyocytes. Activation of the ERK and often, AKT, pathway constituents is associated with pro-proliferative actions. However, in our study, we found that ERKs were activated simultaneously with a suppression of cell cycle activity. We cannot explain this finding. However, others have reported that ERK activation can be associated with elevations in p21 when cell cycle activity is suppressed.<sup>
<xref ref-type="bibr" rid="bibr39-1933719111432860">39</xref>,<xref ref-type="bibr" rid="bibr40-1933719111432860">40</xref>
</sup> Thus, the immature cardiomyocyte appears to display a similar behavior.</p>
<p>In humans, but not in sheep, elevated levels of thyroid hormone in maternal plasma lead to elevated fetal thyroid hormone levels throughout gestation.<sup>
<xref ref-type="bibr" rid="bibr24-1933719111432860">24</xref>
<xref ref-type="bibr" rid="bibr25-1933719111432860"/>–<xref ref-type="bibr" rid="bibr26-1933719111432860">26</xref>,<xref ref-type="bibr" rid="bibr41-1933719111432860">41</xref>
</sup> Thus, fetal hyperthyroidism is associated with maternal hyperthyroidism. The monocarboxylate transporter, which transports T<sub>3</sub> and T<sub>4</sub>, has been identified in human placentas<sup>
<xref ref-type="bibr" rid="bibr28-1933719111432860">28</xref>
</sup> and appears to be the primary placental transporter for thyroid hormones. Maternal levels of circulating total T<sub>4</sub> (∼110 ng/mL) and circulating total T<sub>3</sub> (∼2.0 ng/mL) are elevated during normal pregnancy.<sup>
<xref ref-type="bibr" rid="bibr42-1933719111432860">42</xref>,<xref ref-type="bibr" rid="bibr43-1933719111432860">43</xref>
</sup> Normal human umbilical artery levels of T<sub>4</sub> (90.5 ± 0.02 ng/mL) and T<sub>3</sub> (1.9 ± 0.96 ng/mL) at birth are similar to fetal sheep levels.<sup>
<xref ref-type="bibr" rid="bibr19-1933719111432860">19</xref>,<xref ref-type="bibr" rid="bibr44-1933719111432860">44</xref>
</sup>
</p>
<p>We have recently reported that in 130 days ovine fetuses, exogenous elevation of T<sub>3</sub> to levels normally found at term (145 dGA) stimulates the maturation of cardiomyocytes by suppressing proliferation, increasing binucleation and stimulating the sarcoplasmic reticulum transport protein SERCA2a.<sup>
<xref ref-type="bibr" rid="bibr23-1933719111432860">23</xref>
</sup> In these experiments, p21 levels were elevated and cyclin D1 levels suppressed as predicted by the effects of T<sub>3</sub> on isolated 135 dGA cardiomyocytes.<sup>
<xref ref-type="bibr" rid="bibr14-1933719111432860">14</xref>
</sup> Thus, it is likely that the in vitro studies are reliable indicators of expected responses to thyroid conditions in the womb. The role of p21 and cyclin D1 in regulating the cell cycle under the influence of thyroid hormone remains uncertain even though these 2 proteins change in a direction predictive of their regulatory function.</p>
<p>The results of our studies suggest that elevated T<sub>3</sub> would suppress cardiomyocyte proliferation in vivo even in cardiomyocytes that are normally dividing rapidly. We predict that the rates of cell division in the immature cardiomyocytes of mammals would be deleteriously suppressed by hyperthyroid conditions. If the suppressive effect of T<sub>3</sub> on ovine cardiomyocyte cell cycle activity also occurs in human cardiomyocytes, elevated levels of maternal T<sub>3</sub> at midgestation might lead to fetal hearts with a reduced endowment of cardiomyocytes. Such an effect could compromise the myocardium for life.</p>
</sec>
<sec id="section18-1933719111432860">
<title>Conclusions</title>
<p>The last third of ovine gestation is a critical window of development for the myocardium because it is the period of time when cardiac myocytes mature and their numbers are set at birth. During this period, both mononucleated and binucleated myocyte populations are sensitive to nutritional, hormonal, and hemodynamic modification.<sup>
<xref ref-type="bibr" rid="bibr4-1933719111432860">4</xref>,<xref ref-type="bibr" rid="bibr10-1933719111432860">10</xref>,<xref ref-type="bibr" rid="bibr12-1933719111432860">12</xref>
</sup> This report shows that cardiomyocytes that have not yet begun to enter the terminal differential phase and nearly 30 to 40 days away from seeing the naturally occurring prepartum T<sub>3</sub> increase are nevertheless very sensitive to the mitotic suppression effects of T<sub>3</sub>. The findings suggest that the myocardium would be negatively impacted if thyroid levels were to exceed normal concentrations at midgestation. If midgestation human cardiomyocytes are as sensitive to elevated thyroid levels as the sheep cardiomyocytes in this study, maternal hyperthyroid levels could lead to an underendowed myocardium at birth.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>The authors thank Drs Stephen Back and Roger Hohimer for the generous donations of control fetal sheep tissue for this study as well as Mr Robert Webber and Ms Loni Socha for excellent technical assistance. Drs Perrie O’Tierney and Sonnet Jonker provided sound advice.</p>
</ack>
<fn-group>
<fn fn-type="conflict" id="fn1-1933719111432860">
<p>The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn2-1933719111432860">
<p>The author(s) disclosed receipt of the following financial support for the research, authorship and/or publication of this article: supported by <grant-sponsor>NIH</grant-sponsor><?release-delay 12|0?> grants <grant-sponsor>NICHD</grant-sponsor> P01 HD <grant-num>34430</grant-num>, <grant-sponsor>NINDS</grant-sponsor> R37, <grant-num>NS045737</grant-num>, <grant-sponsor>NHLBI</grant-sponsor> R21 <grant-num>HL093617</grant-num>, and R01 <grant-num>HL102763</grant-num>; <grant-sponsor>NNC</grant-sponsor> was supported by <grant-sponsor>NHLBI</grant-sponsor> training grant <grant-num>T32HL094294</grant-num> and KLT was supported by the M. Lowell Edwards Endowment.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1933719111432860">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jonker</surname>
<given-names>SS</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Louey</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Giraud</surname>
<given-names>GD</given-names>
</name>
<name>
<surname>Thornburg</surname>
<given-names>KL</given-names>
</name>
<name>
<surname>Faber</surname>
<given-names>JJ</given-names>
</name>
</person-group>. <article-title>Myocyte enlargement, differentiation, and proliferation kinetics in the fetal sheep heart</article-title>. <source>J Appl Physiol</source>. <year>2007</year>;<volume>102</volume>(<issue>3</issue>):<fpage>1130</fpage>–<lpage>1142</lpage>.</citation>
</ref>
<ref id="bibr2-1933719111432860">
<label>2</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Rakusan</surname>
<given-names>K</given-names>
</name>
</person-group>. <article-title>Cardiac growth, maturation, and aging</article-title>. In: <person-group person-group-type="editor">
<name>
<surname>Zak</surname>
<given-names>R</given-names>
</name>
</person-group>, ed. <source>Growth of the Heart in Health and Disease</source>. <publisher-loc>New York, NY</publisher-loc>: <publisher-name>Raven Press</publisher-name>; <year>1984</year>:<fpage>131</fpage>–<lpage>164</lpage>.</citation>
</ref>
<ref id="bibr3-1933719111432860">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Clubb</surname>
<given-names>FJ</given-names>
<suffix>Jr</suffix>
</name>
<name>
<surname>Bishop</surname>
<given-names>SP</given-names>
</name>
</person-group>. <article-title>Formation of binucleated myocardial cells in the neonatal rat. An index for growth hypertrophy</article-title>. <source>Lab Invest</source>. <year>1984</year>;<volume>50</volume>(<issue>5</issue>):<fpage>571</fpage>–<lpage>577</lpage>.</citation>
</ref>
<ref id="bibr4-1933719111432860">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barbera</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Giraud</surname>
<given-names>GD</given-names>
</name>
<name>
<surname>Reller</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Maylie</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Morton</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Thornburg</surname>
<given-names>KL</given-names>
</name>
</person-group>. <article-title>Right ventricular systolic pressure load alters myocyte maturation in fetal sheep</article-title>. <source>Am J Physiol Regul Integr Comp Physiol</source>. <year>2000</year>;<volume>279</volume>(<issue>4</issue>):<fpage>R1157</fpage>–<lpage>R1164</lpage>.</citation>
</ref>
<ref id="bibr5-1933719111432860">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Soonpaa</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>KK</given-names>
</name>
<name>
<surname>Pajak</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Franklin</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Field</surname>
<given-names>LJ</given-names>
</name>
</person-group>. <article-title>Cardiomyocyte DNA synthesis and binucleation during murine development</article-title>. <source>Am J Physiol</source>. <year>1996</year>;<volume>271</volume>(<issue>5 pt 2</issue>):<fpage>H2183</fpage>–<lpage>H2189</lpage>.</citation>
</ref>
<ref id="bibr6-1933719111432860">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Smolich</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Walker</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Campbell</surname>
<given-names>GR</given-names>
</name>
<name>
<surname>Adamson</surname>
<given-names>TM</given-names>
</name>
</person-group>. <article-title>Left and right ventricular myocardial morphometry in fetal, neonatal, and adult sheep</article-title>. <source>Am J Physiol</source>. <year>1989</year>;<volume>257</volume>(<issue>1 pt 2</issue>):<fpage>H1</fpage>–<lpage>H9</lpage>.</citation>
</ref>
<ref id="bibr7-1933719111432860">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bugaisky</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Zak</surname>
<given-names>R</given-names>
</name>
</person-group>. <article-title>Cellular growth of cardiac muscle after birth</article-title>. <source>Tex Rep Biol Med</source>. <year>1979</year>;<volume>39</volume>:<fpage>123</fpage>–<lpage>138</lpage>.</citation>
</ref>
<ref id="bibr8-1933719111432860">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zak</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Kizu</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bugaisky</surname>
<given-names>L</given-names>
</name>
</person-group>. <article-title>Cardiac hypertrophy: its characteristics as a growth process</article-title>. <source>Am J Cardiol</source>. <year>1979</year>;<volume>44</volume>(<issue>5</issue>):<fpage>941</fpage>–<lpage>946</lpage>.</citation>
</ref>
<ref id="bibr9-1933719111432860">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>L</given-names>
</name>
</person-group>. <article-title>Prenatal hypoxia and cardiac programming</article-title>. <source>J Soc Gynecol Investig</source>. <year>2005</year>;<volume>12</volume>(<issue>1</issue>):<fpage>2</fpage>–<lpage>13</lpage>.</citation>
</ref>
<ref id="bibr10-1933719111432860">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sundgren</surname>
<given-names>NC</given-names>
</name>
<name>
<surname>Giraud</surname>
<given-names>GD</given-names>
</name>
<name>
<surname>Schultz</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Lasarev</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Stork</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Thornburg</surname>
<given-names>KL</given-names>
</name>
</person-group>. <article-title>Extracellular signal-regulated kinase and phosphoinositol-3 kinase mediate IGF-1 induced proliferation of fetal sheep cardiomyocytes</article-title>. <source>Am J Physiol Regul Integr Comp Physiol</source>. <year>2003</year>;<volume>285</volume>(<issue>6</issue>):<fpage>R1481</fpage>–<lpage>R1489</lpage>.</citation>
</ref>
<ref id="bibr11-1933719111432860">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sundgren</surname>
<given-names>NC</given-names>
</name>
<name>
<surname>Giraud</surname>
<given-names>GD</given-names>
</name>
<name>
<surname>Stork</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Maylie</surname>
<given-names>JG</given-names>
</name>
<name>
<surname>Thornburg</surname>
<given-names>KL</given-names>
</name>
</person-group>. <article-title>Angiotensin II stimulates hyperplasia but not hypertrophy in immature ovine cardiomyocytes</article-title>. <source>J Physiol</source>. <year>2003</year>;<volume>548</volume>(<issue>pt 3</issue>):<fpage>881</fpage>–<lpage>891</lpage>.</citation>
</ref>
<ref id="bibr12-1933719111432860">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Giraud</surname>
<given-names>GD</given-names>
</name>
<name>
<surname>Louey</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Jonker</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Schultz</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Thornburg</surname>
<given-names>KL</given-names>
</name>
</person-group>. <article-title>Cortisol stimulates cell cycle activity in the cardiomyocyte of the sheep fetus</article-title>. <source>Endocrinology</source>. <year>2006</year>;<volume>147</volume>(<issue>8</issue>):<fpage>3643</fpage>–<lpage>3649</lpage>.</citation>
</ref>
<ref id="bibr13-1933719111432860">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>O'Tierney</surname>
<given-names>PF</given-names>
</name>
<name>
<surname>Chattergoon</surname>
<given-names>NN</given-names>
</name>
<name>
<surname>Louey</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Giraud</surname>
<given-names>GD</given-names>
</name>
<name>
<surname>Thornburg</surname>
<given-names>KL</given-names>
</name>
</person-group>. <article-title>Atrial Natriuretic Peptide Inhibits Angiotensin II-Stimulated Proliferation in Fetal Cardiomyocytes</article-title>. <source>J Physiol</source>. <year>2010</year>;<volume>558</volume>(<issue>pt 15</issue>):<fpage>2879</fpage>–<lpage>2889</lpage>.</citation>
</ref>
<ref id="bibr14-1933719111432860">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chattergoon</surname>
<given-names>NN</given-names>
</name>
<name>
<surname>Giraud</surname>
<given-names>GD</given-names>
</name>
<name>
<surname>Thornburg</surname>
<given-names>KL</given-names>
</name>
</person-group>. <article-title>Thyroid hormone inhibits proliferation of fetal cardiac myocytes in vitro</article-title>. <source>J Endocrinol</source>. <year>2007</year>;<volume>192</volume>(<issue>2</issue>):<fpage>R1</fpage>–<lpage>R8</lpage>.</citation>
</ref>
<ref id="bibr15-1933719111432860">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Louey</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Jonker</surname>
<given-names>SS</given-names>
</name>
<name>
<surname>Giraud</surname>
<given-names>GD</given-names>
</name>
<name>
<surname>Thornburg</surname>
<given-names>KL</given-names>
</name>
</person-group>. <article-title>Placental insufficiency decreases cell cycle activity and terminal maturation in fetal sheep cardiomyocytes</article-title>. <source>J Physiol</source>. <year>2007</year>;<volume>580</volume>(<issue>pt 2</issue>):<fpage>639</fpage>–<lpage>648</lpage>.</citation>
</ref>
<ref id="bibr16-1933719111432860">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hopkins</surname>
<given-names>PS</given-names>
</name>
<name>
<surname>Thorburn</surname>
<given-names>GD</given-names>
</name>
</person-group>. <article-title>The effects of foetal thyroidectomy on the development of the ovine foetus</article-title>. <source>J Endocrinol</source>. <year>1972</year>;<volume>54</volume>(<issue>1</issue>):<fpage>55</fpage>–<lpage>66</lpage>.</citation>
</ref>
<ref id="bibr17-1933719111432860">
<label>17</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Thorburn</surname>
<given-names>GD</given-names>
</name>
<name>
<surname>Hopkins</surname>
<given-names>PS</given-names>
</name>
</person-group>. <article-title>Thyroid function in the foetal lamb</article-title>. In: <person-group person-group-type="editor">
<name>
<surname>Comline</surname>
<given-names>KS</given-names>
</name>
<name>
<surname>Cross</surname>
<given-names>KW</given-names>
</name>
<name>
<surname>Dawes</surname>
<given-names>GS</given-names>
</name>
<name>
<surname>Nathanielsz</surname>
<given-names>PW</given-names>
</name>
</person-group>, eds. <source>Foetal and Neonatal Physiology: Proceedings of the Sir Joseph Barcroft Centenary Symposium Held at the Physiological Laboratory Cambridge</source>
<publisher-loc>. Texas</publisher-loc>: <publisher-name>Cambridge University Press</publisher-name>; <year>1973</year>:<fpage>488</fpage>–<lpage>507</lpage>.</citation>
</ref>
<ref id="bibr18-1933719111432860">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chopra</surname>
<given-names>IJ</given-names>
</name>
<name>
<surname>Carlson</surname>
<given-names>HE</given-names>
</name>
<name>
<surname>Solomon</surname>
<given-names>DH</given-names>
</name>
</person-group>. <article-title>Comparison of inhibitory effects of 3,5,3'-triiodothyronine (T3), thyroxine (T4), 3,3,',5'-triiodothyronine (rT3), and 3,3'-diiodothyronine (T2) on thyrotropin-releasing hormone-induced release of thyrotropin in the rat in vitro</article-title>. <source>Endocrinology</source>. <year>1978</year>;<volume>103</volume>(<issue>2</issue>):<fpage>393</fpage>–<lpage>402</lpage>.</citation>
</ref>
<ref id="bibr19-1933719111432860">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Polk</surname>
<given-names>DH</given-names>
</name>
</person-group>. <article-title>Thyroid hormone metabolism during development</article-title>. <source>Reprod Fertil Dev</source>. <year>1995</year>;<volume>7</volume>(<issue>3</issue>):<fpage>469</fpage>–<lpage>477</lpage>.</citation>
</ref>
<ref id="bibr20-1933719111432860">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fowden</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Mundy</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Silver</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Developmental regulation of glucogenesis in the sheep fetus during late gestation</article-title>. <source>J Physiol</source>. <year>1998</year>;<volume>508</volume>(<issue>pt 3</issue>):<fpage>937</fpage>–<lpage>947</lpage>.</citation>
</ref>
<ref id="bibr21-1933719111432860">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Forhead</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Curtis</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kaptein</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Visser</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>Fowden</surname>
<given-names>AL</given-names>
</name>
</person-group>. <article-title>Developmental control of iodothyronine deiodinases by cortisol in the ovine fetus and placenta near term</article-title>. <source>Endocrinology</source>. <year>2006</year>;<volume>147</volume>(<issue>12</issue>):<fpage>5988</fpage>–<lpage>5994</lpage>.</citation>
</ref>
<ref id="bibr22-1933719111432860">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thomas</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Krane</surname>
<given-names>EJ</given-names>
</name>
<name>
<surname>Nathanielsz</surname>
<given-names>PW</given-names>
</name>
</person-group>. <article-title>Changes in the fetal thyroid axis after induction of premature parturition by low dose continuous intravascular cortisol infusion to the fetal sheep at 130 days of gestation</article-title>. <source>Endocrinology</source>. <year>1978</year>;<volume>103</volume>(<issue>1</issue>):<fpage>17</fpage>–<lpage>23</lpage>.</citation>
</ref>
<ref id="bibr23-1933719111432860">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chattergoon</surname>
<given-names>NN</given-names>
</name>
<name>
<surname>Giraud</surname>
<given-names>GD</given-names>
</name>
<name>
<surname>Louey</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Stork</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Fowden</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Thornburg</surname>
<given-names>KL</given-names>
</name>
</person-group>. <article-title>Thyroid hormone drives fetal cardiomyocyte maturation</article-title>. <source>FASEB J</source>. <year>2012</year>;<volume>26</volume>(<issue>1</issue>):<fpage>397</fpage>–<lpage>408</lpage>.</citation>
</ref>
<ref id="bibr24-1933719111432860">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chan</surname>
<given-names>SY</given-names>
</name>
<name>
<surname>Vasilopoulou</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Kilby</surname>
<given-names>MD</given-names>
</name>
</person-group>. <article-title>The role of the placenta in thyroid hormone delivery to the fetus</article-title>. <source>Nat Clin Pract Endocrinol Metab</source>. <year>2009</year>;<volume>5</volume>(<issue>1</issue>):<fpage>45</fpage>–<lpage>54</lpage>.</citation>
</ref>
<ref id="bibr25-1933719111432860">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Higuchi</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Kumagai</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kobayashi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Minami</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Koyama</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Ishii</surname>
<given-names>Y</given-names>
</name>
</person-group>. <article-title>Short-term hyperthyroidism followed by transient pituitary hypothyroidism in a very low birth weight infant born to a mother with uncontrolled Graves' disease</article-title>. <source>Pediatrics</source>. <year>2001</year>;<volume>107</volume>(<issue>4</issue>):<fpage>E57</fpage>.</citation>
</ref>
<ref id="bibr26-1933719111432860">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Calvo</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Obregon</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Escobar</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Morreale</surname>
<given-names>DE</given-names>
</name>
</person-group>. <article-title>The rat placenta and the transfer of thyroid hormones from the mother to the fetus. Effects of maternal thyroid status</article-title>. <source>Endocrinology</source>. <year>1992</year>;<volume>131</volume>(<issue>1</issue>):<fpage>357</fpage>–<lpage>365</lpage>.</citation>
</ref>
<ref id="bibr27-1933719111432860">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kilby</surname>
<given-names>MD</given-names>
</name>
<name>
<surname>Barber</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Hobbs</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Franklyn</surname>
<given-names>JA</given-names>
</name>
</person-group>. <article-title>Thyroid hormone action in the placenta</article-title>. <source>Placenta</source>. <year>2005</year>;<volume>26</volume>(<issue>2-3</issue>):<fpage>105</fpage>–<lpage>113</lpage>.</citation>
</ref>
<ref id="bibr28-1933719111432860">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chan</surname>
<given-names>SY</given-names>
</name>
<name>
<surname>Franklyn</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Pemberton</surname>
<given-names>HN</given-names>
</name>
<etal/>
</person-group>. <article-title>Monocarboxylate transporter 8 expression in the human placenta: the effects of severe intrauterine growth restriction</article-title>. <source>J Endocrinol</source>. <year>2006</year>;<volume>189</volume>(<issue>3</issue>):<fpage>465</fpage>–<lpage>471</lpage>.</citation>
</ref>
<ref id="bibr29-1933719111432860">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jonker</surname>
<given-names>SS</given-names>
</name>
<name>
<surname>Faber</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>DF</given-names>
</name>
<name>
<surname>Thornburg</surname>
<given-names>KL</given-names>
</name>
<name>
<surname>Louey</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Giraud</surname>
<given-names>GD</given-names>
</name>
</person-group>. <article-title>Sequential growth of fetal sheep cardiac myocytes in response to simultaneous arterial and venous hypertension</article-title>. <source>Am J Physiol Regul Integr Comp Physiol</source>. <year>2007</year>;<volume>292</volume>(<issue>2</issue>):<fpage>R913</fpage>–<lpage>R919</lpage>.</citation>
</ref>
<ref id="bibr30-1933719111432860">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Burton</surname>
<given-names>PB</given-names>
</name>
<name>
<surname>Raff</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Kerr</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Yacoub</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Barton</surname>
<given-names>PJ</given-names>
</name>
</person-group>. <article-title>An intrinsic timer that controls cell-cycle withdrawal in cultured cardiac myocytes</article-title>. <source>Dev Biol</source>. <year>1999</year>;<volume>216</volume>(<issue>2</issue>):<fpage>659</fpage>–<lpage>670</lpage>.</citation>
</ref>
<ref id="bibr31-1933719111432860">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kuzman</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Gerdes</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Kobayashi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>Q</given-names>
</name>
</person-group>. <article-title>Thyroid hormone activates Akt and prevents serum starvation-induced cell death in neonatal rat cardiomyocytes</article-title>. <source>J Mol Cell Cardiol</source>. <year>2005</year>;<volume>39</volume>(<issue>5</issue>):<fpage>841</fpage>–<lpage>844</lpage>.</citation>
</ref>
<ref id="bibr32-1933719111432860">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Polk</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Reviczky</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Vu</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Fisher</surname>
<given-names>DA</given-names>
</name>
</person-group>. <article-title>Thyroxine sulfate is a major thyroid hormone metabolite and a potential intermediate in the monodeiodination pathways in fetal sheep</article-title>. <source>Endocrinology</source>. <year>1992</year>;<volume>131</volume>(<issue>4</issue>):<fpage>1751</fpage>–<lpage>1756</lpage>.</citation>
</ref>
<ref id="bibr33-1933719111432860">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Polk</surname>
<given-names>DH</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>SY</given-names>
</name>
<name>
<surname>Wright</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Reviczky</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Fisher</surname>
<given-names>DA</given-names>
</name>
</person-group>. <article-title>Ontogeny of thyroid hormone effect on tissue 5'-monodeiodinase activity in fetal sheep</article-title>. <source>Am J Physiol</source>. <year>1988</year>;<volume>254</volume>(<issue>3 pt 1</issue>):<fpage>E337</fpage>–<lpage>E341</lpage>.</citation>
</ref>
<ref id="bibr34-1933719111432860">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lin</surname>
<given-names>HY</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>HY</given-names>
</name>
<etal/>
</person-group>. <article-title>L-Thyroxine vs. 3,5,3'-triiodo-<sc>l</sc>-thyronine and cell proliferation: activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase</article-title>. <source>Am J Physiol Cell Physiol</source>. <year>2009</year>;<volume>296</volume>(<issue>5</issue>):<fpage>C980</fpage>–<lpage>C991</lpage>.</citation>
</ref>
<ref id="bibr35-1933719111432860">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hu</surname>
<given-names>LW</given-names>
</name>
<name>
<surname>Benvenuti</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Liberti</surname>
<given-names>EA</given-names>
</name>
<name>
<surname>Carneiro-Ramos</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Barreto-Chaves</surname>
<given-names>ML</given-names>
</name>
</person-group>. <article-title>Thyroxine-induced cardiac hypertrophy: influence of adrenergic nervous system versus renin-angiotensin system on myocyte remodeling</article-title>. <source>Am J Physiol Regul Integr Comp Physiol</source>. <year>2003</year>;<volume>285</volume>(<issue>6</issue>):<fpage>R1473</fpage>–<lpage>R1480</lpage>.</citation>
</ref>
<ref id="bibr36-1933719111432860">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Polk</surname>
<given-names>DH</given-names>
</name>
<name>
<surname>Callegari</surname>
<given-names>CC</given-names>
</name>
<name>
<surname>Newnham</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Effect of fetal thyroidectomy on newborn thermogenesis in lambs</article-title>. <source>Pediatr Res</source>. <year>1987</year>;<volume>21</volume>(<issue>5</issue>):<fpage>453</fpage>–<lpage>457</lpage>.</citation>
</ref>
<ref id="bibr37-1933719111432860">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matsui</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Nagoshi</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Rosenzweig</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Akt and PI 3-kinase signaling in cardiomyocyte hypertrophy and survival</article-title>. <source>Cell Cycle</source>. <year>2003</year>;<volume>2</volume>(<issue>3</issue>):<fpage>220</fpage>–<lpage>223</lpage>.</citation>
</ref>
<ref id="bibr38-1933719111432860">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kato</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Muraski</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>Atrial natriuretic peptide promotes cardiomyocyte survival by cGMP-dependent nuclear accumulation of zyxin and Akt</article-title>. <source>J Clin Invest</source>. <year>2005</year>;<volume>115</volume>(<issue>10</issue>):<fpage>2716</fpage>–<lpage>2730</lpage>.</citation>
</ref>
<ref id="bibr39-1933719111432860">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Heath</surname>
<given-names>V</given-names>
</name>
<name>
<surname>O'Garra</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Johnston</surname>
<given-names>J</given-names>
</name>
<name>
<surname>McMahon</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Sustained activation of the raf-MEK-ERK pathway elicits cytokine unresponsiveness in T cells</article-title>. <source>J Immunol</source>. <year>1999</year>;<volume>163</volume>(<issue>11</issue>):<fpage>5796</fpage>–<lpage>5805</lpage>.</citation>
</ref>
<ref id="bibr40-1933719111432860">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dangi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>FM</given-names>
</name>
<name>
<surname>Shapiro</surname>
<given-names>P</given-names>
</name>
</person-group>. <article-title>Activation of extracellular signal-regulated kinase (ERK) in G2 phase delays mitotic entry through p21CIP1</article-title>. <source>Cell Prolif</source>. <year>2006</year>;<volume>39</volume>(<issue>4</issue>):<fpage>261</fpage>–<lpage>279</lpage>.</citation>
</ref>
<ref id="bibr41-1933719111432860">
<label>41</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Haddow</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Palomaki</surname>
<given-names>GE</given-names>
</name>
<name>
<surname>Allan</surname>
<given-names>WC</given-names>
</name>
<etal/>
</person-group>. <article-title>Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child</article-title>. <source>N Engl J Med</source>. <year>1999</year>;<volume>341</volume>(<issue>8</issue>):<fpage>549</fpage>–<lpage>555</lpage>.</citation>
</ref>
<ref id="bibr42-1933719111432860">
<label>42</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Niswander</surname>
<given-names>KR</given-names>
</name>
<name>
<surname>Gordon</surname>
<given-names>M</given-names>
</name>
</person-group>, <source>The Collaborative Perinatal Study of the National Institute of Neurological Disease and Stroke: The Women and Their Babies. Report</source>. <publisher-loc>Philadelphia, PA</publisher-loc>: <publisher-name>W.B. Saunders Company</publisher-name>; <year>1972</year>: <fpage>246</fpage>–<lpage>249</lpage>.</citation>
</ref>
<ref id="bibr43-1933719111432860">
<label>43</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Seely</surname>
<given-names>BL</given-names>
</name>
<name>
<surname>Burrow</surname>
<given-names>GN</given-names>
</name>
</person-group>. <article-title>Thyroid disease and pregnancy</article-title>. In: <person-group person-group-type="editor">
<name>
<surname>Creasy</surname>
<given-names>RK</given-names>
</name>
<name>
<surname>Resnik</surname>
<given-names>R</given-names>
</name>
</person-group>, eds. <source>Maternal-Fetal Medicine: Principles and Practice</source>. <publisher-loc>Philadelphia, PA</publisher-loc>: <publisher-name>W.B. Saunders Company</publisher-name>; <year>1994</year>.</citation>
</ref>
<ref id="bibr44-1933719111432860">
<label>44</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hume</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Simpson</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Delahunty</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group>. <article-title>Human fetal and cord serum thyroid hormones: developmental trends and interrelationships</article-title>. <source>J Clin Endocrinol Metab</source>. <year>2004</year>;<volume>89</volume>(<issue>8</issue>):<fpage>4097</fpage>–<lpage>4103</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>